WallStreetZenWallStreetZen

NASDAQ: ADAP
Adaptimmune Therapeutics PLC Stock Ownership - Who owns Adaptimmune Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Adaptimmune Therapeutics PLC insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
John LungerChief Patient Supply Officer2024-01-1712,805$0.67
$8.62kSell
Elliot NorryChief Medical Officer2024-01-175,309$0.67
$3.57kSell
Elliot NorryChief Medical Officer2024-01-1712,967$0.67
$8.73kSell
William C. Bertrand Jr.Chief Operating Officer2024-01-1713,599$0.67
$9.15kSell
William C. Bertrand Jr.Chief Operating Officer2024-01-175,309$0.67
$3.57kSell
Adrian RawcliffeChief Executive Officer2024-01-1730,080$0.67
$20.24kSell
John LungerChief Patient Supply Officer2024-01-175,309$0.67
$3.57kSell
Elliot NorryChief Medical Officer2024-01-162,287$0.79
$1.81kSell
John LungerChief Patient Supply Officer2024-01-164,681$0.79
$3.70kSell
Adrian RawcliffeChief Executive Officer2024-01-169,304$0.79
$7.35kSell

1 of 3

ADAP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ADAP insiders and whales buy or sell their stock.

ADAP Shareholders

What type of owners hold Adaptimmune Therapeutics PLC stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Ecor1 Capital LLC11.10%164,424,420$187.44MInsider
David M. Mott10.92%161,747,668$184.39MInsider
Anthony A. Florence Jr.10.92%161,747,668$184.39MInsider
Scott D. Sandell10.92%161,747,668$184.39MInsider
Peter W. Sonsini10.92%161,747,668$184.39MInsider
Forest Baskett10.92%161,747,668$184.39MInsider
Ravi Viswanathan10.42%154,247,668$175.84MInsider
Peter J. Barris10.42%154,247,668$175.84MInsider
Patrick J. Kerins9.61%142,247,668$162.16MInsider
M. James Barrett9.61%142,247,668$162.16MInsider

1 of 3

ADAP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ADAP7.28%92.72%Net Selling
INZY54.64%45.36%Net BuyingNet Selling
VNDA56.23%43.77%Net SellingNet Selling
BDTX60.10%39.90%Net BuyingNet Buying
HOWL48.08%51.92%
View Top Biotech Stocks

Adaptimmune Therapeutics Stock Ownership FAQ

Who owns Adaptimmune Therapeutics?

Adaptimmune Therapeutics (NASDAQ: ADAP) is owned by 9.69% institutional shareholders, 123.49% Adaptimmune Therapeutics insiders, and 0.00% retail investors. Ecor1 Capital LLC is the largest individual Adaptimmune Therapeutics shareholder, owning 164.42M shares representing 11.10% of the company. Ecor1 Capital LLC's Adaptimmune Therapeutics shares are currently valued at $177.58M.

If you're new to stock investing, here's how to buy Adaptimmune Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.